SOD1 (Superoxide dismutase [Cu-Zn]) variants and mutations
SOD1 (also known as Superoxide dismutase [Cu-Zn]) is a human protein-coding gene encoding a superoxide dismutase [Cu-Zn] protein. It detoxifies superoxide radicals in the cytosol and mitochondrial intermembrane space, limiting oxidative injury. Pathogenic variants cause amyotrophic lateral sclerosis mainly through toxic properties of mutant protein rather than simple loss of antioxidant activity. This analysis covers 419 SOD1 variants and mutations. Of these, 92% have computational variant effect predictions. Disease context includes amyotrophic lateral sclerosis, spastic tetraplegia and axial hypotonia, progressive, and motor neuron disorder. Example SOD1 variants include A2V, T3M, and T3R.
Variant analysis overview
- Gene: SOD1
- Protein: Superoxide dismutase [Cu-Zn]
- UniProt accession: P00441
- Organism: Homo sapiens
- Variants analyzed: 419
- Variant scope: all variants
- Completed: 2026-08-10
Variant and mutation evidence
- Variant composition: 279 unspecified-consequence records; 52 missense variants; 65 synonymous variants; 8 frameshift variants; 5 splice-region variants; 2 in-frame deletions; 3 stop-gained variants; 1 splice acceptor variant; 4 substitution
- Prediction scores: 385 variants have prediction scores (92% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: amyotrophic lateral sclerosis, spastic tetraplegia and axial hypotonia, progressive, motor neuron disorder, neurodegenerative disease, familial amyotrophic lateral sclerosis, sporadic amyotrophic lateral sclerosis, frontotemporal dementia with motor neuron disease, Limb muscle weakness, Atrophy/Degeneration affecting the central nervous system, skull disorder, Abnormal central motor function, alcohol drinking.
Protein structure and variant hotspots
- Protein features: 8 binding sites; 12 post-translational modification sites.
- PTM context: 22 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, LitVar.
Notable SOD1 variants
Examples include A2V, T3M, T3R, K4E, K4R, K4K, K4N, A5S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2V (p.Ala2Val), cosmic curated COSV54255, gnomAD rs1297567794, REVEL 0.36, MetaLR 0.95
- T3M (p.Thr3Met), NCI-TCGA Cosmic COSV9953, cosmic curated COSV99532, TOPMed rs1601153292, REVEL 0.38, MetaLR 0.94, Uncertain significance, SOD1-related disorder
- T3R (p.Thr3Arg), gnomAD 21-31659777-C-G, REVEL 0.34, MetaLR 0.97
- K4E (p.Lys4Glu), rs1568807297, ClinGen CA410035877, ClinVar RCV003064620, ClinVar RCV004700918, REVEL 0.80, MetaLR 0.99, Pathogenic, not provided; Amyotrophic lateral sclerosis type 1
- K4R (p.Lys4Arg), NCI-TCGA Cosmic COSV5425, cosmic curated COSV54255, MetaLR 0.99, MetaSVM 1.16, Variant assessed as somatic; moderate impact.
- K4K (p.Lys4Lys), gnomAD 21-31659781-G-A, CADD 15.20
- K4N (p.Lys4Asn), gnomAD 21-31659781-G-T, REVEL 0.60, MetaLR 0.99
- A5S (p.Ala5Ser), rs121912444, ClinGen CA410035885, ClinVar RCV001095541, UniProt VAR 013518, AlphaMissense 0.55, MetaLR 0.99, Pathogenic, Amyotrophic lateral sclerosis type 1
- A5T (p.Ala5Thr), rs121912444, ClinGen CA257337, ClinVar RCV000015887, ClinVar RCV000518527, REVEL 0.85, AlphaMissense 0.55, Pathogenic, not provided; Amyotrophic lateral sclerosis type 1
- A5V (p.Ala5Val), rs121912442, ClinGen CA257333, ClinVar RCV000015885, ClinVar RCV000518025, REVEL 0.85, MetaLR 0.99, Pathogenic, not provided; Amyotrophic lateral sclerosis type 1
- A5A (p.Ala5Ala), rs199766524, gnomAD 21-31659784-C-T, CADD 10.60
- V6A (p.Val6Ala), rs2123427988, ClinGen CA410035892, ClinVar RCV001910988, Ensembl rs2123427988, Uncertain significance, Amyotrophic lateral sclerosis type 1
- V6L (p.Val6Leu), Ensembl rs1568807314
- V6M (p.Val6Met), rs1568807314, ClinGen CA410035888, ClinVar RCV002605188, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- V6C (p.Val6Cys), rs1568807304, gnomAD 21-31659782-GC-G, CADD 31.00
- V6V (p.Val6Val), gnomAD 21-31659787-G-A, CADD 14.40
- C7F (p.Cys7Phe), rs121912448, ClinGen CA257343, ClinVar RCV000015894, UniProt VAR 008717, AlphaMissense 0.94, MetaLR 0.99, Pathogenic, Amyotrophic lateral sclerosis type 1
- C7G (p.Cys7Gly), rs1312702973, ClinGen CA410035896, ClinVar RCV002016002, gnomAD rs1312702973, AlphaMissense 0.69, MetaLR 0.99, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- C7S (p.Cys7Ser), rs1312702973, ClinGen CA410035894, ClinVar RCV002015993, gnomAD rs1312702973, AlphaMissense 0.69, MetaLR 0.99, Pathogenic, Amyotrophic lateral sclerosis type 1
- C7Y (p.Cys7Tyr), gnomAD rs121912448, MetaLR 0.99, MetaSVM 1.00, Uncertain significance, Amyotrophic lateral sclerosis type 1
- C7C (p.Cys7Cys), gnomAD 21-31659790-C-T, CADD 15.10
- V8E (p.Val8Glu), rs1568807330, UniProt VAR 007132, Ensembl rs1568807330, AlphaMissense 0.71, MetaLR 0.98, Pathogenic, in ALS1
- V8M (p.Val8Met), gnomAD rs1380854315, REVEL 0.86, MetaLR 0.99
- L9Q (p.Leu9Gln), rs1568807342, ClinGen CA410035909, ClinVar RCV003050563, UniProt VAR 013519, AlphaMissense 0.94, MetaLR 0.99, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- L9V (p.Leu9Val), rs1568807333, ClinGen CA410035908, ClinVar RCV001939974, ClinVar RCV006266953, REVEL 0.70, MetaLR 0.97, Uncertain significance, Amyotrophic lateral sclerosis type 1; not specified
- L9L (p.Leu9Leu), gnomAD 21-31659796-G-C, CADD 14.60
- K10Q (p.Lys10Gln), TOPMed rs1236713490, gnomAD rs1236713490, REVEL 0.61, MetaLR 0.96
- K10N (p.Lys10Asn), gnomAD 21-31659799-G-C, REVEL 0.72, MetaLR 0.97
- G11A (p.Gly11Ala), Ensembl rs1555836167, Pathogenic, SOD1-related disorder
- G11R (p.Gly11Arg), Ensembl rs1568807350
- G11V (p.Gly11Val), rs1555836167, Ensembl rs1555836167, AlphaMissense 0.40, MetaLR 0.98, Pathogenic
- G11S (p.Gly11Ser), gnomAD 21-31659800-G-A, REVEL 0.85, MetaLR 0.98
- G11G (p.Gly11Gly), gnomAD 21-31659802-C-T, CADD 14.10
- D12A (p.Asp12Ala), Ensembl rs1568807374, MetaLR 0.97, MetaSVM 1.20
- D12Y (p.Asp12Tyr), rs762628133, ClinGen CA9998857, ClinVar RCV003486397, ClinVar RCV006276342, REVEL 0.65, MetaLR 0.99, Conflicting interpretations, not provided; Amyotrophic lateral sclerosis type 1
- D12N (p.Asp12Asn), gnomAD 21-31659803-G-A, REVEL 0.43, MetaLR 0.97
- D12G (p.Asp12Gly), gnomAD 21-31659804-A-G, REVEL 0.48, MetaLR 0.97
- D12E (p.Asp12Glu), gnomAD 21-31659805-C-A, REVEL 0.25, MetaLR 0.95
- D12D (p.Asp12Asp), rs2123428025, gnomAD 21-31659805-C-T, CADD 9.03
- G13A (p.Gly13Ala), TOPMed rs1379845624
- G13D (p.Gly13Asp), TOPMed rs1379845624, REVEL 0.51, MetaLR 0.98
- G13R (p.Gly13Arg), rs121912456, ClinGen CA257360, ClinVar RCV000015903, UniProt VAR 013521, AlphaMissense 0.40, MetaLR 0.99, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- G13S (p.Gly13Ser), gnomAD 21-31659806-G-A, REVEL 0.43, MetaLR 0.97
- G13G (p.Gly13Gly), rs377178013, gnomAD 21-31659808-C-T, CADD 12.90
- P14S (p.Pro14Ser), gnomAD 21-31659809-C-T, REVEL 0.39, MetaLR 0.96
- V15A (p.Val15Ala), TOPMed rs1202989817, gnomAD rs1202989817, REVEL 0.71, AlphaMissense 0.56, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- V15G (p.Val15Gly), rs1202989817, ClinGen CA410036010, ClinVar RCV002016007, UniProt VAR 013522, AlphaMissense 0.56, MetaLR 1.00, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- V15L (p.Val15Leu), rs1568807400, ClinGen CA410036007, ClinVar RCV002029618, Ensembl rs1568807400, AlphaMissense 0.72, MetaLR 1.00, Pathogenic/Likely pathogenic, Amyotrophic lateral sclerosis type 1
- V15M (p.Val15Met), rs1568807400, ClinGen CA410036005, ClinVar RCV001095542, UniProt VAR 007133, AlphaMissense 0.72, MetaLR 1.00, Pathogenic/Likely pathogenic, Amyotrophic lateral sclerosis type 1
- V15V (p.Val15Val), rs1251222457, gnomAD 21-31659814-G-A, CADD 10.10
- Q16E (p.Gln16Glu), gnomAD rs2049531483, REVEL 0.31, MetaLR 0.93
- Q16R (p.Gln16Arg), TOPMed rs200016533, gnomAD rs200016533, REVEL 0.28, MetaLR 0.95
- Q16H (p.Gln16His), gnomAD 21-31659817-G-C, REVEL 0.27, MetaLR 0.92
- Q16Q (p.Gln16Gln), gnomAD 21-31659817-G-A, CADD 8.72
- G17A (p.Gly17Ala), rs1200906022, ClinGen CA410036027, ClinVar RCV000713408, ClinVar RCV001386880, AlphaMissense 0.85, MetaLR 1.00, Pathogenic/Likely pathogenic, Amyotrophic lateral sclerosis type 1; not provided
- G17C (p.Gly17Cys), rs121912453, ClinGen CA410036024, ClinVar RCV001971733, gnomAD rs121912453, REVEL 0.86, AlphaMissense 0.94, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- G17S (p.Gly17Ser), rs121912453, ClinGen CA257353, ClinVar RCV000015899, UniProt VAR 007134, AlphaMissense 0.94, MetaLR 1.00, Pathogenic, Amyotrophic lateral sclerosis type 1
- G17V (p.Gly17Val), gnomAD 21-31659819-G-T, REVEL 0.90, MetaLR 1.00
- G17G (p.Gly17Gly), rs200454724, gnomAD 21-31659820-C-A, CADD 13.10
- I18V (p.Ile18Val), gnomAD rs1460554436, REVEL 0.31, MetaLR 0.83
- I18T (p.Ile18Thr), gnomAD 21-31659822-T-C, REVEL 0.33, MetaLR 0.76
- I18I (p.Ile18Ile), rs1447729350, gnomAD 21-31659823-C-T, CADD 16.30
- I19F (p.Ile19Phe), rs2516654131, ClinGen CA410036042, ClinVar RCV002828336, Uncertain significance, Amyotrophic lateral sclerosis type 1
- I19M (p.Ile19Met), gnomAD rs1182088847, REVEL 0.76, MetaLR 0.99
- I19T (p.Ile19Thr), rs1601153438, ClinGen CA410036046, ClinVar RCV000808197, Ensembl rs1601153438, AlphaMissense 0.94, MetaLR 0.99, Uncertain significance, Amyotrophic lateral sclerosis type 1
- I19del (p.Ile19del), gnomAD 21-31659819-GCAT-, CADD 19.50
- I19I (p.Ile19Ile), rs1182088847, gnomAD 21-31659826-C-T, CADD 15.80
- N20H (p.Asn20His), Ensembl rs1601153445
- N20I (p.Asn20Ile), rs768029813, ClinGen CA410036059, ClinVar RCV003630996, AlphaMissense 0.09, MetaLR 0.87, Uncertain significance, Amyotrophic lateral sclerosis type 1
- N20S (p.Asn20Ser), rs768029813, ClinGen CA9998859, ClinVar RCV000611073, ClinVar RCV000689563, REVEL 0.30, AlphaMissense 0.09, Conflicting interpretations, not specified; Amyotrophic lateral sclerosis type 1
- F21C (p.Phe21Cys), rs1555836169, ClinGen CA410036072, ClinVar RCV001958950, UniProt VAR 045876, AlphaMissense 0.92, MetaLR 0.99, Pathogenic, Amyotrophic lateral sclerosis type 1
- F21L (p.Phe21Leu), rs1555836170, ClinGen CA410036078, ClinVar RCV001065949, ClinVar RCV005036375, REVEL 0.89, MetaLR 0.98, Pathogenic/Likely pathogenic, Spastic tetraplegia and axial hypotonia, progressive; Amyotrophic lateral sclero
- E22G (p.Glu22Gly), rs1568807435, UniProt VAR 013523, Ensembl rs1568807435, AlphaMissense 0.44, MetaLR 0.98, Pathogenic, in ALS1
- E22K (p.Glu22Lys), rs121912450, ClinGen CA257347, ClinVar RCV000015896, UniProt VAR 007135, AlphaMissense 0.34, MetaLR 0.94, Pathogenic, Amyotrophic lateral sclerosis type 1
- E22* (p.Glu22Ter), gnomAD 21-31659833-G-T, CADD 38.00
- E22E (p.Glu22Glu), rs756458346, gnomAD 21-31659835-G-A, CADD 12.90
- Q23H (p.Gln23His), rs1424217272, gnomAD rs1424217272, ClinGen CA410036102, ClinVar RCV002020327, REVEL 0.81, MetaLR 0.99, Conflicting interpretations, SOD1-related disorder; not provided; Amyotrophic lateral sclerosis type 1
- Q23L (p.Gln23Leu), rs1169198442, ClinGen CA410036099, ClinVar RCV001095543, UniProt VAR 045877, AlphaMissense 0.77, MetaLR 0.99, Pathogenic/Likely pathogenic, Amyotrophic lateral sclerosis type 1
- Q23P (p.Gln23Pro), rs1169198442, ClinGen CA410036097, ClinVar RCV003628666, AlphaMissense 0.77, MetaLR 0.99, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- Q23R (p.Gln23Arg), TOPMed rs1169198442, gnomAD rs1169198442, REVEL 0.79, AlphaMissense 0.77, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- Q23Q (p.Gln23Gln), gnomAD 21-31659838-G-A, CADD 12.10
- K24Q (p.Lys24Gln), gnomAD 21-31659839-A-C, REVEL 0.41, MetaLR 0.90
- K24K (p.Lys24Lys), rs1467183070, gnomAD 21-31659841-G-A, CADD 24.20
- K24N (p.Lys24Asn), gnomAD 21-31659841-G-T, REVEL 0.46, MetaLR 0.93
- E25* (p.Glu25Ter), gnomAD 21-31663785-TAAAG, CADD 24.70
- E25G (p.Glu25Gly), gnomAD 21-31663791-A-G, REVEL 0.28, MetaLR 0.92
- S26N (p.Ser26Asn), ExAC rs747214897, gnomAD rs747214897, REVEL 0.23, MetaLR 0.93
- S26T (p.Ser26Thr), ExAC rs747214897, gnomAD rs747214897, MetaLR 0.96, MetaSVM 1.54
- N27S (p.Asn27Ser), gnomAD 21-31663797-A-G, REVEL 0.34, MetaLR 0.91
- N27N (p.Asn27Asn), rs1489004175, gnomAD 21-31663798-T-C, CADD 7.72
- G28D (p.Gly28Asp), gnomAD 21-31663798-TG-T, CADD 23.10
- G28R (p.Gly28Arg), gnomAD 21-31663799-G-A, REVEL 0.44, MetaLR 0.98
- G28G (p.Gly28Gly), rs1217375069, gnomAD 21-31663801-A-G, CADD 11.60
- P29R (p.Pro29Arg), Ensembl rs11556621, REVEL 0.46, MetaLR 0.99
- P29Q (p.Pro29Gln), gnomAD 21-31663803-C-A, REVEL 0.40, MetaLR 0.98
- P29P (p.Pro29Pro), rs145198224, gnomAD 21-31663804-A-G, CADD 1.32
- V30A (p.Val30Ala), Ensembl rs1568809118, MetaLR 0.99, MetaSVM 1.00
- V30V (p.Val30Val), rs748040402, gnomAD 21-31663807-G-A, CADD 4.62
- K31N (p.Lys31Asn), rs2123431867, ClinGen CA410036568, ClinVar RCV001887489, Ensembl rs2123431867, AlphaMissense 0.32, MetaLR 0.95, Uncertain significance, Amyotrophic lateral sclerosis type 1
- K31M (p.Lys31Met), gnomAD 21-31663809-A-T, REVEL 0.34, MetaLR 0.95
- K31R (p.Lys31Arg), gnomAD 21-31663809-A-G, REVEL 0.17, MetaLR 0.91
- V32A (p.Val32Ala), rs1428716759, ClinGen CA410036578, ClinVar RCV001095392, ClinVar RCV001196130, AlphaMissense 0.77, MetaLR 0.99, Conflicting interpretations, not provided; Amyotrophic lateral sclerosis type 1; Spastic tetraplegia and axia
- V32G (p.Val32Gly), TOPMed rs1428716759, gnomAD rs1428716759, REVEL 0.78, AlphaMissense 0.77, Likely pathogenic
- V32L (p.Val32Leu), gnomAD 21-31663811-G-T, REVEL 0.35, MetaLR 0.94
- V32V (p.Val32Val), rs769715106, gnomAD 21-31663813-G-A, CADD 0.08
- W33* (p.Trp33Ter), TOPMed rs1319528534, NCI-TCGA TCGA novel, CADD 29.00, Variant assessed as somatic; high impact.
- W33R (p.Trp33Arg), rs2049569572, ClinGen CA410036582, ClinVar RCV001093459, Ensembl rs2049569572, AlphaMissense 0.20, MetaLR 0.81, Uncertain significance, not provided
- S35I (p.Ser35Ile), ExAC rs777560607, TOPMed rs777560607, gnomAD rs777560607, REVEL 0.24, MetaLR 0.94
- S35N (p.Ser35Asn), ExAC rs777560607, TOPMed rs777560607, gnomAD rs777560607
- S35R (p.Ser35Arg), NCI-TCGA Cosmic COSV9953, cosmic curated COSV99532, MetaLR 0.90, MetaSVM 0.72, Variant assessed as somatic; moderate impact.
- S35G (p.Ser35Gly), gnomAD 21-31663820-A-G, REVEL 0.32, MetaLR 0.93
- S35T (p.Ser35Thr), gnomAD 21-31663821-G-C, REVEL 0.22, MetaLR 0.89
- S35S (p.Ser35Ser), gnomAD 21-31663822-C-T, CADD 4.40
- I36F (p.Ile36Phe), rs1057524474, ClinGen CA16608530, ClinVar RCV000435550, ClinVar RCV002525490, AlphaMissense 0.61, MetaLR 0.98, Uncertain significance, Amyotrophic lateral sclerosis type 1; not provided
- K37Q (p.Lys37Gln), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K37R (p.Lys37Arg), Ensembl rs2049569647, MetaLR 0.09, MetaSVM -0.98
- K37K (p.Lys37Lys), rs1374061515, gnomAD 21-31663828-A-G, CADD 5.68
- G38R (p.Gly38Arg), rs121912431, ClinGen CA410036643, ClinVar RCV000664220, Ensembl rs121912431, AlphaMissense 0.86, MetaLR 1.00, Pathogenic, Amyotrophic lateral sclerosis type 1
- G38V (p.Gly38Val), Ensembl rs1555836517, MetaLR 1.00, MetaSVM 0.88
- G38G (p.Gly38Gly), rs1405534640, gnomAD 21-31663831-A-G, CADD 5.16
- L39Q (p.Leu39Gln), rs1555836520, ClinGen CA410036655, ClinVar RCV003041393, Ensembl rs1555836520, AlphaMissense 0.95, MetaLR 1.00, Likely pathogenic, Amyotrophic lateral sclerosis type 1
- L39R (p.Leu39Arg), rs1555836520, UniProt VAR 013524, Ensembl rs1555836520, AlphaMissense 0.95, MetaLR 1.00, Pathogenic, in ALS1
- L39V (p.Leu39Val), rs121912432, ClinGen CA257313, ClinVar RCV000015875, ClinVar RCV000997816, AlphaMissense 0.54, MetaLR 0.99, Pathogenic/Likely pathogenic, not provided; Amyotrophic lateral sclerosis type 1
- L39L (p.Leu39Leu), rs200072460, gnomAD 21-31663834-G-T, CADD 5.10
- T40I (p.Thr40Ile), Ensembl rs1804450, MetaLR 0.98, MetaSVM 1.26
- E41G (p.Glu41Gly), rs1568809149, ClinGen CA410036675, ClinVar RCV000697630, Ensembl rs1568809149, AlphaMissense 0.13, MetaLR 0.96, Pathogenic/Likely pathogenic, Amyotrophic lateral sclerosis type 1
- E41R (p.Glu41Arg), gnomAD 21-31663837-T-TA, CADD 26.50
- E41K (p.Glu41Lys), gnomAD 21-31663838-G-A, REVEL 0.45, MetaLR 0.93
- G42C (p.Gly42Cys), NCI-TCGA Cosmic COSV5425, cosmic curated COSV54257, Variant assessed as somatic; moderate impact., in ALS1
- G42D (p.Gly42Asp), rs121912434, ClinGen CA257317, ClinVar RCV000015877, UniProt VAR 007139, AlphaMissense 0.75, MetaLR 0.99, Pathogenic, Amyotrophic lateral sclerosis type 1
- G42S (p.Gly42Ser), rs121912433, ClinGen CA257315, ClinVar RCV000015876, ClinVar RCV002496378, AlphaMissense 0.52, MetaLR 0.99, Pathogenic, Spastic tetraplegia and axial hypotonia, progressive; Amyotrophic lateral sclero
- L43L (p.Leu43Leu), gnomAD 21-31663846-G-A, CADD 0.41
- H44R (p.His44Arg), rs121912435, ClinGen CA257319, ClinVar RCV000015878, ClinVar RCV000713397, REVEL 0.91, MetaLR 0.99, Pathogenic, not provided; Amyotrophic lateral sclerosis type 10; Amyotrophic lateral scleros
- H44Y (p.His44Tyr), gnomAD 21-31663847-C-T, REVEL 0.91, MetaLR 0.99
- H44H (p.His44His), gnomAD 21-31663849-T-C, CADD 0.79
- G45G (p.Gly45Gly), gnomAD 21-31663852-A-G, CADD 10.70
- F46C (p.Phe46Cys), rs121912457, ClinGen CA257362, ClinVar RCV000015904, UniProt VAR 013525, AlphaMissense 0.98, MetaLR 0.99, Pathogenic, Amyotrophic lateral sclerosis type 1
- F46S (p.Phe46Ser), Ensembl rs121912457, MetaLR 0.99, MetaSVM 1.03, Pathogenic, in ALS1
- F46V (p.Phe46Val), gnomAD 21-31663853-T-G, REVEL 0.98, MetaLR 0.99
- F46F (p.Phe46Phe), rs1421563256, gnomAD 21-31663855-C-T, CADD 9.45
- F46L (p.Phe46Leu), gnomAD 21-31663855-C-G, REVEL 0.91, MetaLR 0.99
- H47D (p.His47Asp), ExAC rs748897491, gnomAD rs748897491
- H47R (p.His47Arg), rs121912443, ClinGen CA257335, ClinVar RCV000015886, ClinVar RCV000281824, AlphaMissense 0.98, MetaLR 0.99, Pathogenic, not provided; Amyotrophic lateral sclerosis; Amyotrophic lateral sclerosis type
- H47Y (p.His47Tyr), cosmic curated COSV54256, ExAC rs748897491, gnomAD rs748897491, MetaLR 1.00, MetaSVM 0.90
- H47P (p.His47Pro), gnomAD 21-31663857-A-C, REVEL 0.98, MetaLR 1.00
- V48A (p.Val48Ala), rs1568809169, ClinGen CA410036743, ClinVar RCV001318269, Ensembl rs1568809169, AlphaMissense 0.91, MetaLR 0.99, Pathogenic/Likely pathogenic, Amyotrophic lateral sclerosis type 1
- V48I (p.Val48Ile), Ensembl rs1555836523, Uncertain significance, not provided; Amyotrophic lateral sclerosis type 1
- V48F (p.Val48Phe), Ensembl rs1555836523, MetaLR 0.99, MetaSVM 0.92, Likely pathogenic, SOD1-related disorder
- H49D (p.His49Asp), NCI-TCGA Cosmic COSV5425, cosmic curated COSV54255, Variant assessed as somatic; moderate impact., in ALS1
- H49Q (p.His49Gln), rs1568809175, UniProt VAR 007142, Ensembl rs1568809175, AlphaMissense 0.99, MetaLR 1.00, Pathogenic, in ALS1
- H49R (p.His49Arg), rs1568809172, ClinGen CA410036753, cosmic curated COSV10609, ClinVar RCV000995880, AlphaMissense 0.98, MetaLR 1.00, Pathogenic/Likely pathogenic, not provided; Amyotrophic lateral sclerosis type 1
- H49N (p.His49Asn), gnomAD 21-31663862-C-A, REVEL 0.92, MetaLR 1.00
- H49H (p.His49His), gnomAD 21-31663864-T-C, CADD 6.06
- E50K (p.Glu50Lys), rs1568809178, ClinGen CA410036759, ClinVar RCV000815816, ClinVar RCV004745611, AlphaMissense 0.40, MetaLR 0.99, Uncertain significance, Amyotrophic lateral sclerosis type 1
- E50V (p.Glu50Val), ExAC rs770404622, MetaLR 0.98, MetaSVM 1.33
- E50G (p.Glu50Gly), rs752237082, gnomAD 21-31663865-GA-G, CADD 26.00
- E50* (p.Glu50Ter), gnomAD 21-31663865-G-T, CADD 35.00
- E50E (p.Glu50Glu), rs201045805, gnomAD 21-31663867-G-A, CADD 7.10
- F51C (p.Phe51Cys), ExAC rs759149157, gnomAD rs759149157, REVEL 0.93, MetaLR 0.99
- F51L (p.Phe51Leu), gnomAD 21-31663868-T-C, REVEL 0.89, MetaLR 0.98
- G52G (p.Gly52Gly), gnomAD 21-31663873-A-G, CADD 11.20
- D53D (p.Asp53Asp), rs1276917683, gnomAD 21-31663876-T-C, CADD 7.24
- T55R (p.Thr55Arg), rs986277034, UniProt VAR 045879, Ensembl rs986277034, REVEL 0.92, MetaLR 0.99, Uncertain significance, not specified
- T55K (p.Thr55Lys), gnomAD 21-31663880-AC-A, CADD 28.80
- T55I (p.Thr55Ile), gnomAD 21-31663881-C-T, REVEL 0.95, MetaLR 1.00
- A56V (p.Ala56Val), TOPMed rs2049570429, REVEL 0.41, MetaLR 0.97
- A56E (p.Ala56Glu), gnomAD 21-31663884-C-A, REVEL 0.40, MetaLR 0.96
- G57D (p.Gly57Asp), Ensembl rs2049593777, SIFT 0.00
- G57G (p.Gly57Gly), gnomAD 21-31666450-C-T, CADD 15.60, SIFT 0.02
- C58R (p.Cys58Arg), TOPMed rs1568810255, MetaLR 0.99, MetaSVM 0.92
- C58Y (p.Cys58Tyr), gnomAD 21-31666452-G-A, REVEL 0.97, MetaLR 0.99
- C58S (p.Cys58Ser), gnomAD 21-31666452-G-C, REVEL 0.92, MetaLR 0.99
- T59I (p.Thr59Ile), gnomAD 21-31666455-C-T, REVEL 0.46, MetaLR 0.93
- S60I (p.Ser60Ile), rs1413388444, ClinGen CA410037222, ClinVar RCV002224612, TOPMed rs1413388444, REVEL 0.94, MetaLR 1.00, Uncertain significance, not provided
- S60N (p.Ser60Asn), rs1413388444, ClinGen CA410037220, ClinVar RCV003630041, TOPMed rs1413388444, REVEL 0.88, MetaLR 1.00, Uncertain significance, Amyotrophic lateral sclerosis type 1
- S60S (p.Ser60Ser), rs373888553, gnomAD 21-31666459-T-C, CADD 13.20, SIFT 0.26
- A61E (p.Ala61Glu), gnomAD rs1378635853, REVEL 0.94, MetaLR 0.99
- A61P (p.Ala61Pro), NCI-TCGA Cosmic COSV5425, cosmic curated COSV54256, MetaLR 0.99, MetaSVM 0.91, Variant assessed as somatic; moderate impact.
- A61T (p.Ala61Thr), NCI-TCGA Cosmic COSV5425, REVEL 0.87, MetaLR 0.98, Variant assessed as somatic; moderate impact.
- A61V (p.Ala61Val), gnomAD 21-31666461-C-T, REVEL 0.92, MetaLR 0.99
Public SOD1 analysis runs
- SOD1 analysis run — SOD1 (419 variants) — completed 2026-08-10